S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:ERAS

Erasca (ERAS) Stock Forecast, Price & News

$2.71
+0.09 (+3.44%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.59
$2.74
50-Day Range
$2.57
$3.15
52-Week Range
$2.49
$10.74
Volume
740,612 shs
Average Volume
937,893 shs
Market Capitalization
$408.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Erasca MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
318.2% Upside
$11.33 Price Target
Short Interest
Bearish
12.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Erasca in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$339,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.29) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

325th out of 1,006 stocks

Pharmaceutical Preparations Industry

149th out of 492 stocks


ERAS stock logo

About Erasca (NASDAQ:ERAS) Stock

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Erasca Earnings Preview
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Erasca (ERAS) Receives a Buy from Goldman Sachs
Mizuho Securities Sticks to Their Buy Rating for Erasca (ERAS)
Erasca, Inc. (NASDAQ:ERAS) Short Interest Up 12.0% in March
Erasca (ERAS) Gets a Buy from Mizuho Securities
Mizuho Securities Remains a Buy on Erasca (ERAS)
Erasca (NASDAQ:ERAS) Earns Buy Rating from Analysts at Mizuho
Erasca spikes as CEO reports stock purchase
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

ERAS Company Calendar

Last Earnings
3/23/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+324.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-242,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.57 per share

Miscellaneous

Free Float
94,118,000
Market Cap
$402.08 million
Optionable
Not Optionable
Beta
1.10

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 51)
    Co-Founder, Chairman & CEO
    Comp: $850.23k
  • Mr. Ebun S. Garner J.D. (Age 51)
    Esq., Gen. Counsel & Corp. Sec.
    Comp: $510.98k
  • Dr. Wei Lin M.D. (Age 53)
    Chief Medical Officer
    Comp: $1M
  • Dr. Michael D. Varney Ph.D. (Age 65)
    Chairman of R&D, Scientific Advisory Board Member and Director
    Comp: $78.38k
  • Dr. David M. Chacko M.D. (Age 39)
    Chief Financial Officer
  • Dr. Nik Chetwyn Ph.D.
    Sr. VP of Operations
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 56)
    M.S., MS, CPA, Sr. VP of Fin.
  • Ms. Chandra D. Lovejoy (Age 52)
    Sr. VP of Regulatory Affairs
  • Dr. Robert Shoemaker Ph.D. (Age 42)
    Sr. VP of Research













ERAS Stock - Frequently Asked Questions

Should I buy or sell Erasca stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares.
View ERAS analyst ratings
or view top-rated stocks.

What is Erasca's stock price forecast for 2023?

3 analysts have issued 1-year target prices for Erasca's shares. Their ERAS share price forecasts range from $9.00 to $15.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 324.5% from the stock's current price.
View analysts price targets for ERAS
or view top-rated stocks among Wall Street analysts.

How have ERAS shares performed in 2023?

Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 38.1% and is now trading at $2.67.
View the best growth stocks for 2023 here
.

Are investors shorting Erasca?

Erasca saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 10,340,000 shares, a decrease of 9.2% from the April 30th total of 11,390,000 shares. Based on an average daily volume of 924,800 shares, the days-to-cover ratio is presently 11.2 days. Approximately 12.5% of the company's stock are sold short.
View Erasca's Short Interest
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02.

When did Erasca IPO?

(ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

What is Erasca's stock symbol?

Erasca trades on the NASDAQ under the ticker symbol "ERAS."

Who are Erasca's major shareholders?

Erasca's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.88%), BlackRock Inc. (3.57%), Bank of America Corp DE (1.98%), Geode Capital Management LLC (1.01%), Renaissance Technologies LLC (0.97%) and International Biotechnology Trust PLC (0.95%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends
.

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Erasca's stock price today?

One share of ERAS stock can currently be purchased for approximately $2.67.

How much money does Erasca make?

Erasca (NASDAQ:ERAS) has a market capitalization of $402.08 million. The company earns $-242,800,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Erasca have?

The company employs 123 workers across the globe.

How can I contact Erasca?

The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com.

This page (NASDAQ:ERAS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -